This Week in Cardiology Feb 20 2026 This Week in Cardiology
8 snips
Feb 20, 2026 Six‑year TAVR vs SAVR outcomes and concerns about valve durability and late reinterventions. Problems interpreting mortality signals and conflicting meta‑analyses. Ethical and documentation issues around unilateral DNR orders. New long‑term data showing targeted hypothermia provides no neurologic or survival benefit. Sham‑controlled HFpEF device trial design praised. Observational links between GLP‑1 therapy and reduced AF recurrence.
AI Snips
Chapters
Transcript
Episode notes
Discuss Long-Term Tradeoffs With Patients
- Discuss long-term valve reliability, re-intervention risk, and stroke with low-risk patients when choosing TAVR versus SAVR.
- Frame decisions around patient values and the trade-off between less invasiveness now and potential later risks.
Crossing Curves Break Standard Analysis
- Kaplan-Meier analyses assume proportional hazards, but TAVR shows early benefit then later harm, violating that assumption.
- This non-proportionality can hide meaningful late differences and requires different analytic approaches.
Meta-Analysis Favors Surgery At Five Years
- An updated meta-analysis found a 12% relative increase in five-year mortality with TAVR versus SAVR in low-risk patients.
- Posterior probabilities favored SAVR, adding weight to concerns about long-term TAVR outcomes.